Tumor necrosis factor α in the onset and progression of leukemia.

Abstract

Tumor necrosis factor alpha (TNF-α), originally described as an anti-neoplastic cytokine, has been found, in apparent contradiction to its name, to play an important role in promoting the development and progression of malignant disease. Targeting TNF-α with TNF antagonists has elicited an objective response in certain solid tumors in phase I and II clinical trials. This review focuses on the relationship of TNF-α expressed by leukemia cells and adverse clinical features of leukemia. TNF-α is involved in all steps of leukemogenesis, including cellular transformation, proliferation, angiogenesis, and extramedullary infiltration. TNF-α is also an important factor in the tumor microenvironment and assists leukemia cells in immune evasion, survival, and resistance to chemotherapy. TNF-α may be a potent target for leukemia therapy.

• Authors: Xiaoxi Zhou, Zhuoya Li, Jianfeng Zhou
• Journal: Experimental hematology (Exp Hematol) Vol. 45 Pg. 17-26 (Jan 2017) ISSN: 1873-2399 [Electronic] Netherlands
• PMID: 27833035 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2016 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.

Chemical References

• Antineoplastic Agents
• Tumor Necrosis Factor-alpha

Topics

• Animals
• Antineoplastic Agents (pharmacology, therapeutic use)
• Cell Survival
• Disease Progression
• Humans
• Leukemia (diagnosis, drug therapy, etiology, metabolism)
• Molecular Targeted Therapy
• Neoplastic Stem Cells (drug effects, metabolism)
• Neovascularization, Pathologic
• Signal Transduction (drug effects)
• Tumor Microenvironment (immunology)
• Tumor Necrosis Factor-alpha (antagonists & inhibitors, metabolism)